- Home
- IBIO vs ICU Comparison
IBIO vs ICU Comparison
Compare IBIO & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- ICU
- Stock Information
- Founded
- IBIO 2008
- ICU 2018
- Country
- IBIO United States
- ICU United States
- Employees
- IBIO N/A
- ICU N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- ICU Health Care
- Exchange
- IBIO Nasdaq
- ICU Nasdaq
- Market Cap
- IBIO 16.4M
- ICU 15.9M
- IPO Year
- IBIO N/A
- ICU N/A
- Fundamental
- Price
- IBIO $1.54
- ICU $0.57
- Analyst Decision
- IBIO Strong Buy
- ICU
- Analyst Count
- IBIO 4
- ICU 0
- Target Price
- IBIO $4.50
- ICU N/A
- AVG Volume (30 Days)
- IBIO 7.2M
- ICU 1.7M
- Earning Date
- IBIO 10-31-2025
- ICU 11-13-2025
- Dividend Yield
- IBIO N/A
- ICU N/A
- EPS Growth
- IBIO N/A
- ICU N/A
- EPS
- IBIO N/A
- ICU N/A
- Revenue
- IBIO $400,000.00
- ICU $766,000.00
- Revenue This Year
- IBIO N/A
- ICU $820.00
- Revenue Next Year
- IBIO N/A
- ICU $63.37
- P/E Ratio
- IBIO N/A
- ICU N/A
- Revenue Growth
- IBIO 77.78
- ICU N/A
- 52 Week Low
- IBIO $0.56
- ICU $0.31
- 52 Week High
- IBIO $6.89
- ICU $3.57
- Technical
- Relative Strength Index (RSI)
- IBIO 77.05
- ICU 39.98
- Support Level
- IBIO $1.02
- ICU $0.60
- Resistance Level
- IBIO $1.72
- ICU $0.65
- Average True Range (ATR)
- IBIO 0.19
- ICU 0.05
- MACD
- IBIO 0.06
- ICU 0.00
- Stochastic Oscillator
- IBIO 80.82
- ICU 26.62
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.